Soticlestat, formerly known as TAK-935/OV935, is an investigational drug developed by Takeda Pharmaceuticals. It is a highly selective, potent inhibitor of the enzyme cholesterol 24-hydroxylase, which plays a crucial role in the regulation of neurosteroid synthesis. Neurosteroids are naturally occurring molecules in the brain that modulate neuronal activity, including in epilepsy. Our recent study adds Read More…
Category: Collaboration
Heterogeneity of Seizure Susceptibility in Alzheimer’s disease
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that affects over 4 million people in the US alone. As the worldwide population continues to age, this number will only grow in the coming decades. Seizures in people with both early- and late-onset AD are more common than in similarly age-matched non-affected individuals. People with epilepsy Read More…
A novel plasma biomarker for seizures?
Gasotransmitters are a relatively untapped therapeutic target in epilepsy. The carbonic anhydrase inhibitor, acetazolamide, is an approved antiseizure drug, and low levels of CO2 have been linked with asynchronous neuronal firing and higher seizure propensity. Nitric oxide is another critical signaling molecule that has undergone a high degree of scrutiny in epilepsy and other neurological Read More…